Literatur
-
1
Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H.
Diet-derived advanced
glycation end products are major contributors to the body’s
AGE pool and induce inflammation in healthy subjects.
Ann
N Y Acad Sci.
2005;
1043
461-466
-
2
Bierhaus A, Humpert P, Stern D, Arnold B, Nawroth P P.
Advanced glycation end product receptor-mediated cellular dysfunction.
Ann NY Acad Sci.
2005;
1043
676-680
-
3
Heidland A, Sebekova K, Schinzel R.
Advanced glycation end products and the progressive course of
renal disease.
Am J Kidney Dis.
2001;
38
S100-S106
-
4
Sebeková K, Wagner Z, Schupp N, Boor P.
Genomic damage and malignancy
in end-stage renal failure: do advanced glycation end products contribute?.
Kidney Blood Press Res.
2007;
30
56-66
-
5
Takeuchi M, Yamagishi S.
Possible involvement
of advanced glycation end-products (AGEs) in the pathogenesis of
Alzheimer’s disease.
Curr Pharm Des.
2008;
14
973-978
-
6
Foell D, Wittkowski H, Roth J.
Mechanisms of disease: a „DAMP” view of inflammatory
arthritis.
Nat Clin Pract Rheumatol.
2007;
3
382-390
-
7
Xiang G, Schinzel R, Simm A, Münch G, Sebekova K. et al .
Advanced glycation end products (AGEs)-induced
expression of TGFß1 is suppressed by a protease in the
tubule cell line LLC-PK1.
Nephrol Dial Transplant.
2001;
16
1562-1569
-
8
Ling H, Vamvakas S, Busch G, Dämmrich J, Schramm L, Lang F, Heidland A.
Suppressing role of transforming growth factorbeta 1 on cathepsin
activity in cultured kidney tubule cells.
Am J Physiol.
1995;
269
F911-917
-
9
Sebeková K, Schinzel R, Ling H, Simm A, Xiang G, Gekle M, Münch G, Vamvakas S, Heidland A.
Advanced glycated albumin impairs protein degradation in the
kidney proximal tubules cell line LLC-PK1.
Cell Mol Biol
(Noisy-le-grand).
1998;
44
1051-1060
-
10
Stopper H, Schinzel R, Sebeková K, Heidland A.
Genotoxicity of advanced
glycation end products in mammalian cells.
Cancer Letters.
2003;
190
151-156
-
11
Stopper H, Schupp N, Bahner U, Sebekova K, Klassen A, Heidland A.
Genomic damage in end-stage
renal failure: potential involvement of advanced glycation end products and
carbonyl stress.
Semin Nephrol.
2004;
24
474-478
-
12
Schupp N, Schinzel R, Heidland A, Stopper H.
Genotoxicity of advanced
glycation end products – potential involvement of AT 1
receptors.
Ann NY Acad Sci.
2005;
1043
685-695
-
13
Park L, Raman K G, Lee K J. et al .
Suppression of accelerated
diabetic atherosclerosis by the soluble receptor for advanced glycation
endproducts.
Nat Med.
1998;
4
1025-1031
-
14
Taguchi A, Blood D C, del Toro G. et al .
Blockade of RAGE-amphoterin signalling
suppresses tumour growth and metastases.
Nature.
2000;
405
354-360
-
15
Yan S D, Chen X, Fu J, Chen M, Zhu H. et al .
RAGE
and amyloid-b; peptide neurotoxicity in Alzheimer’s disease.
Nature.
1996;
382
685-691
-
16
Paczek L, Soin J, Bartolomiejczyk I, Krolak R, Lao M, Heidland A.
Impairment of proteolytic activity
in isolated glomeruli and tubules in experimental diabetic nephropathy.
Clin Nephrol.
1996;
46
258-260
-
17
Sebeková K, Dämmrich J, Fierlbeck W, Krivosiková Z, Paczek L, Heidland A.
Effect
of chronic therapy with proteolytic enzymes on hypertension-induced
renal injury in the rat model of Goldblatt hypertension.
Am
J Nephrol.
1998;
18
570-576
-
18
Sebeková K, Dämmrich J, Krivosíková Z, Heidland A.
The
effect of oral protease administration in the rat remnant kidney model.
Res Exp Med (Berl).
1999;
199
177-188
Prof. Dr. August Heidland
Med. Univ.-Klinik Würzburg und Kuratorium
für Dialyse und Nierentransplantation
Hans-Brandmann-Weg
1
97080 Würzburg
Phone: +49-931-299-9672
Fax: +49-931-299-9673)
Email: August.Heidland@t-online.de
